NCT01593696View on ClinicalTrials.gov

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 29, 2012

Primary Completion Date

November 11, 2016

Study Completion Date

October 2, 2017

Conditions
ALLB Cell LymphomaLeukemiaLarge Cell LymphomaNon-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)

Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01593696 - Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter